Article | August 19, 2021

Optimize Your Dermatology Study With A Data-Informed Protocol Assessment

By Sonja VanWye, RN, MSN, Director of Dermatology Strategy, IQVIA Biotech


How four data-driven protocol design analyses can increase chances of study success in dermatology clinical trials

Nearly 60 percent of clinical trials have protocol amendments,1 often required to address shortcomings in the study design, endpoints which do not support study objectives, excessive assessments which do not support study endpoints,2 or eligibility criteria. Such amendments are a major undertaking, leading to significant timeline delays and additional cost. It is imperative to understand the parts of a clinical trial protocol that could cause potential problems, proactively address them, and maximize the likelihood of study success.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader